1 / 7

Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir in GT1 and Renal Disease RUBY-I

Explore the study design, regimens, drug dosing, baseline characteristics, and conclusions of Ombitasvir-Paritaprevir-Ritonavirand Dasabuvir in GT1 and Renal Disease based on Gastroenterology research.

blacks
Download Presentation

Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir in GT1 and Renal Disease RUBY-I

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Phase 3b Treatment-Naive Ombitasvir-Paritaprevir-Ritonavirand Dasabuvir in GT1 and Renal DiseaseRUBY-I Pockros PJ, Gastroenterology. 2016;150:1590-8.

  2. Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir in GT1 & Renal DiseaseRUBY-I: Study Design Source: Pockros PJ, Gastroenterology. 2016;150:1590-8.

  3. Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir in GT1 & Renal DiseaseRUBY-I: Regimens 0 12 24 Week GT 1an = 13 Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir + Ribavirin SVR12 GT 1bn = 7 Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir SVR12 Drug DosingOmbitasvir-Paritaprevir-Ritonavir (25/150/100 mg once daily)+ Dasabuvir: 250 mg twice dailyRibavirin for patients not on hemodialysis: 200 mg once dailyRibavirin for patients on hemodialysis: 200 mg given 4 hours before each hemodialysis session Source: Pockros PJ, Gastroenterology. 2016;150:1590-8.

  4. Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir in GT1 & Renal DiseaseRUBY-I: Baseline Characteristics Source: Pockros PJ, Gastroenterology. 2016;150:1590-8.

  5. Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir in GT1 & Renal DiseaseRUBY-I: Baseline Results RUBY-I: SVR 12 Rates* 85/88 91/91 13/13 7/7 11/13 7/7 11/13 7/7 OBV/PTV/r + DSV = Ombitasvir-Paritaprevir-Ritonavirand Dasabuvir; RBV = ribavirin Source: Pockros PJ, Gastroenterology. 2016;150:1590-8.

  6. Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir in GT1 & Renal DiseaseRUBY-I: Conclusions Source: Pockros PJ, Gastroenterology. 2016;150:1590-8.

  7. This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects. Hepatitis C Onlinewww.hepatitisc.uw.edu Hepatitis Web Studyhttp://depts.washington.edu/hepstudy/ Funded by a grant from the Centers for Disease Control and Prevention.

More Related